The significant EPS miss and widening losses are concerning, but the strong cash position and FDA endorsement of a surrogate endpoint de-risk the regulatory path. Traders should watch for SAFEGUARD enrollment updates and any partnership or licensing announcements that could validate the platform beyond T1D.
Price Chart
Executive Summary
SAB Biotherapeutics reported Q1 2026 EPS of -$0.35, a 68.3% miss vs consensus of -$0.21, with net loss widening to $18.9M from $5.2M a year ago. The company highlighted continued SAFEGUARD trial enrollment progress, FDA acceptance of C-peptide as a surrogate endpoint for accelerated approval, and a strong $217.6M cash position providing runway through 2028.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.35 missed consensus of -$0.21 by 68.3%
- Net loss widened to $18.9M from $5.2M in Q1 2025
- R&D expenses increased to $13.4M from $7.7M YoY
- Cash position of $217.6M at March 31, 2026, providing runway through 2028
- Completed public offering raising $95M in gross proceeds in March 2026
- SAFEGUARD Phase 2b trial enrollment on track for completion by end of 2026 with topline data expected in 2H 2027
- FDA confirmed C-peptide AUC may serve as surrogate endpoint for accelerated approval
- Phase 1 data showed C-peptide preservation and improved glycemic control in treated patients
Financial Impact
EPS miss of 68.3% vs consensus; net loss increased 263% YoY to $18.9M
Risk Factors
- Clinical trial failure or delay in SAFEGUARD could wipe out pipeline value
- Cash burn rate is accelerating; $217.6M may not be sufficient if trials extend beyond 2028
- Dilution risk from additional capital raises given ongoing losses
- Competition from other T1D disease-modifying therapies (e.g., Teplizumab)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292726 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 7, 2026 12w ago | 8-K | $3.90 $3.17 | ▼ −18.72% | ▼ −20.71% | $2.98 (−23.59%) |
May 29, 2026 18w ago | Press Release | $3.60 $3.62 | ▲ +0.56% | ▼ −0.63% | $2.98 (−17.22%) |
May 12, 2026 20w ago | Press Release | $3.62 $3.85 | ▼ −6.35% | ▼ −1.97% | $2.98 (+17.68%) |
Mar 19, 2026 28w ago | Press Release | $3.75 $3.90 | ▲ +4.00% | ▼ −10.42% | $2.98 (−20.53%) |
Mar 19, 2026 28w ago | 8-K | $3.78 $3.90 | ▼ −3.17% | ▲ +11.17% | $2.98 (+21.16%) |
Mar 18, 2026 28w ago | Press Release | $3.70 $3.38 | ▲ +8.65% | ▲ +20.17% | $2.98 (+19.46%) |
Mar 17, 2026 28w ago | Press Release | $3.70 $3.38 | ▲ +8.65% | ▲ +20.17% | $2.98 (+19.46%) |
Mar 10, 2026 29w ago | Press Release | $4.10 $3.36 | ▼ −18.05% | ▼ −29.73% | $2.98 (−27.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access